Review



eht1864  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    MedChemExpress eht1864
    Eht1864, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 35 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/eht+1864/EHT+1864/pmc13133839-37-9-26
    Average 95 stars, based on 35 article reviews
    eht1864 - by Bioz Stars, 2026-11
    95/100 stars

    Images

    Related Articles

    other:

    Article Title: Context-dependent inhibitory roles of RhoA in 3D invasive cell migration within the extracellular matrix
    Article Snippet: EHT 1864 , MedChemExpress , Cat# HY-16659.

    Article Title: Rabies virus utilizes neuropilin 2 as an endocytic receptor to trigger TGFBR1-mediated actin polymerization
    Article Snippet: Phalloidin iFlour 488 (CN: ab176753) was from Abcam.

    Indirect Immunoperoxidase Assay:

    Article Title: Activation of TMEM16E scramblase induces ligand independent growth factor receptor signaling and macropinocytosis for membrane repair.
    Article Snippet: The mCherry-N1 vectors from Clontech. .. The following chemicals were obtained: Amiloride hydrochloride (Tocris); 10,000MW dextran, Alexa Fluor 680 (Invitrogen); FITC-Dextran 70,000MW (Sigma-Aldrich); afatinib (BIBW 2992, Selleckchem); imatinib (STI571, Selleckchem); wortmannin (Enzo); IPA-3 and EHT-1864 (MCE); oxotremorine-M (Oxo-M; Research Biochemicals), and other chemicals (Sigma-Aldrich). .. Human cDNAs of EGFR (Plasmid #133749) and PDGFR (Plasmid #136455) were purchased from Addgene, and coding regions were subcloned into a pcDNA 3.1(+) vector.



    Similar Products

    95
    MedChemExpress eht1864
    Eht1864, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/eht+1864/EHT+1864/pmc13133839-37-9-26
    Average 95 stars, based on 1 article reviews
    eht1864 - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    93
    TargetMol eht1864
    A Schematic representation of the role of EVs in the FBS on cell migration. FBS was heat-inactivated as a conventional treatment for cell culture, and EVs in it were depleted by ultracentrifugation. Cell migration was measured by the wound healing assay. B Cell migration during the wound healing of WT or CIP4 KO PANC-1 cells in the presence of FBS (Top) or EV-depleted FBS (Bottom). Cell edges at 0 h (dotted lines) and 12 h (solid lines) are shown. Scale bars, 100 μm. C Cell migration in the presence of FBS, EV-depleted FBS, or EV-depleted FBS supplemented with l-EV fraction from FBS (4 × 10 6 cells were treated with 6 × 10 8 EVs/ml in 1 ml). Dynamin inhibitor dynasore was applied at 40 μM. Cell migration areas are the wounded areas occupied by migrated cells after 12 h. Data show the means ± SD from 4 independent experiments. D Illustration of Rac1-containing EVs from HEK293 cell culture medium. E Cell migration in the presence of l-EV fraction from MIM I-BAR-expressing HEK293 cells (4 × 10 6 cells were treated with 1.4 × 10 9 EVs/ml in 1 ml). Dynasore was applied at 40 μM. Data show the means ± SD from 4 independent experiments. F Western blotting of Rac1 in the l-EV fractions of GFP or MIM I-BAR-expressing HEK293 cells and EV fractions from FBS. The number of EVs per lane was indicated. Representative blots from three technical replicates using the same lot of FBS are shown. G Western blotting of MIM in the EV fractions from FBS. A representative blot from the three technical replicates using the same lot of FBS is shown. H Cell migration under the l-EV fraction from FBS treated with the Rac1 inhibitor <t>EHT1864</t> at 20 μM. 4 × 10 6 cells were treated with 6 × 10 8 EVs/ml in 1 ml. Data show the means ± SD from 3 independent experiments. Statistical significance was performed by one-way ANOVA with Tukey’s honestly significant difference (HSD) test. Source data are provided as a file.
    Eht1864, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/eht+1864/EHT+1864+2HCl/pmc12686433-412-5-6
    Average 93 stars, based on 1 article reviews
    eht1864 - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    95
    Tocris eht1864
    Analysis of cross-sensitivity of parental A2780 and Doxo-resistant A2780ADR cells to selected inhibitors of DDR- and DNA repair-related mechanisms. Logarithmically growing parental A2780 and A2780ADR variant cells were treated with selected pharmacological inhibitors of DNA repair (olaparib and niraparib), DDR (prexasertib and rabusertib), HDAC (ricolinistat and entinostat), Rac1 GTPase <t>(EHT1864</t> and Ehop16), drug transport (verapamil) and Topo II (dexrazoxane) at the indicated concentrations. At 72 h after drug addition, viability was monitored by use of the AlamarBlue assay as described in methods. Data shown are the mean ± SD from three independent experiments each performed in biological quadruplicates (n=3; n=4). Dashed lines indicate inhibitory concentrations (IC 20 and IC 50 ). Data obtained from treatment period of 24 h are presented in . For IC 50 after 24 h and 72 h see . Doxo, doxorubicin; DDR, DNA damage response; HDAC, histone deacetylase; SD, standard deviation; EHT, Rac1 inhibitor EHT1864.
    Eht1864, supplied by Tocris, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/eht+1864/EHT+1864/pmc12945421-33-44-48
    Average 95 stars, based on 1 article reviews
    eht1864 - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    95
    Tocris eht 1864 5 5 7 trifluoromethyl quinolin 4 ylthio pentyloxy
    Analysis of cross-sensitivity of parental A2780 and Doxo-resistant A2780ADR cells to selected inhibitors of DDR- and DNA repair-related mechanisms. Logarithmically growing parental A2780 and A2780ADR variant cells were treated with selected pharmacological inhibitors of DNA repair (olaparib and niraparib), DDR (prexasertib and rabusertib), HDAC (ricolinistat and entinostat), Rac1 GTPase <t>(EHT1864</t> and Ehop16), drug transport (verapamil) and Topo II (dexrazoxane) at the indicated concentrations. At 72 h after drug addition, viability was monitored by use of the AlamarBlue assay as described in methods. Data shown are the mean ± SD from three independent experiments each performed in biological quadruplicates (n=3; n=4). Dashed lines indicate inhibitory concentrations (IC 20 and IC 50 ). Data obtained from treatment period of 24 h are presented in . For IC 50 after 24 h and 72 h see . Doxo, doxorubicin; DDR, DNA damage response; HDAC, histone deacetylase; SD, standard deviation; EHT, Rac1 inhibitor EHT1864.
    Eht 1864 5 5 7 Trifluoromethyl Quinolin 4 Ylthio Pentyloxy, supplied by Tocris, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/eht+1864/EHT+1864/us12569494-91-7-26
    Average 95 stars, based on 1 article reviews
    eht 1864 5 5 7 trifluoromethyl quinolin 4 ylthio pentyloxy - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    95
    MedChemExpress eht 1864
    Analysis of cross-sensitivity of parental A2780 and Doxo-resistant A2780ADR cells to selected inhibitors of DDR- and DNA repair-related mechanisms. Logarithmically growing parental A2780 and A2780ADR variant cells were treated with selected pharmacological inhibitors of DNA repair (olaparib and niraparib), DDR (prexasertib and rabusertib), HDAC (ricolinistat and entinostat), Rac1 GTPase <t>(EHT1864</t> and Ehop16), drug transport (verapamil) and Topo II (dexrazoxane) at the indicated concentrations. At 72 h after drug addition, viability was monitored by use of the AlamarBlue assay as described in methods. Data shown are the mean ± SD from three independent experiments each performed in biological quadruplicates (n=3; n=4). Dashed lines indicate inhibitory concentrations (IC 20 and IC 50 ). Data obtained from treatment period of 24 h are presented in . For IC 50 after 24 h and 72 h see . Doxo, doxorubicin; DDR, DNA damage response; HDAC, histone deacetylase; SD, standard deviation; EHT, Rac1 inhibitor EHT1864.
    Eht 1864, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/eht+1864/EHT+1864/pmc12823269-35-0-3
    Average 95 stars, based on 1 article reviews
    eht 1864 - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    93
    MedChemExpress hy 100462 eht 1864 medchemexpress
    Analysis of cross-sensitivity of parental A2780 and Doxo-resistant A2780ADR cells to selected inhibitors of DDR- and DNA repair-related mechanisms. Logarithmically growing parental A2780 and A2780ADR variant cells were treated with selected pharmacological inhibitors of DNA repair (olaparib and niraparib), DDR (prexasertib and rabusertib), HDAC (ricolinistat and entinostat), Rac1 GTPase <t>(EHT1864</t> and Ehop16), drug transport (verapamil) and Topo II (dexrazoxane) at the indicated concentrations. At 72 h after drug addition, viability was monitored by use of the AlamarBlue assay as described in methods. Data shown are the mean ± SD from three independent experiments each performed in biological quadruplicates (n=3; n=4). Dashed lines indicate inhibitory concentrations (IC 20 and IC 50 ). Data obtained from treatment period of 24 h are presented in . For IC 50 after 24 h and 72 h see . Doxo, doxorubicin; DDR, DNA damage response; HDAC, histone deacetylase; SD, standard deviation; EHT, Rac1 inhibitor EHT1864.
    Hy 100462 Eht 1864 Medchemexpress, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/eht+1864/PTP1B-IN-2/pm41359424-233-236-239
    Average 93 stars, based on 1 article reviews
    hy 100462 eht 1864 medchemexpress - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    Image Search Results


    A Schematic representation of the role of EVs in the FBS on cell migration. FBS was heat-inactivated as a conventional treatment for cell culture, and EVs in it were depleted by ultracentrifugation. Cell migration was measured by the wound healing assay. B Cell migration during the wound healing of WT or CIP4 KO PANC-1 cells in the presence of FBS (Top) or EV-depleted FBS (Bottom). Cell edges at 0 h (dotted lines) and 12 h (solid lines) are shown. Scale bars, 100 μm. C Cell migration in the presence of FBS, EV-depleted FBS, or EV-depleted FBS supplemented with l-EV fraction from FBS (4 × 10 6 cells were treated with 6 × 10 8 EVs/ml in 1 ml). Dynamin inhibitor dynasore was applied at 40 μM. Cell migration areas are the wounded areas occupied by migrated cells after 12 h. Data show the means ± SD from 4 independent experiments. D Illustration of Rac1-containing EVs from HEK293 cell culture medium. E Cell migration in the presence of l-EV fraction from MIM I-BAR-expressing HEK293 cells (4 × 10 6 cells were treated with 1.4 × 10 9 EVs/ml in 1 ml). Dynasore was applied at 40 μM. Data show the means ± SD from 4 independent experiments. F Western blotting of Rac1 in the l-EV fractions of GFP or MIM I-BAR-expressing HEK293 cells and EV fractions from FBS. The number of EVs per lane was indicated. Representative blots from three technical replicates using the same lot of FBS are shown. G Western blotting of MIM in the EV fractions from FBS. A representative blot from the three technical replicates using the same lot of FBS is shown. H Cell migration under the l-EV fraction from FBS treated with the Rac1 inhibitor EHT1864 at 20 μM. 4 × 10 6 cells were treated with 6 × 10 8 EVs/ml in 1 ml. Data show the means ± SD from 3 independent experiments. Statistical significance was performed by one-way ANOVA with Tukey’s honestly significant difference (HSD) test. Source data are provided as a file.

    Journal: Nature Communications

    Article Title: Efficient cellular transformation via protein delivery through the protrusion-derived extracellular vesicles

    doi: 10.1038/s41467-025-66351-1

    Figure Lengend Snippet: A Schematic representation of the role of EVs in the FBS on cell migration. FBS was heat-inactivated as a conventional treatment for cell culture, and EVs in it were depleted by ultracentrifugation. Cell migration was measured by the wound healing assay. B Cell migration during the wound healing of WT or CIP4 KO PANC-1 cells in the presence of FBS (Top) or EV-depleted FBS (Bottom). Cell edges at 0 h (dotted lines) and 12 h (solid lines) are shown. Scale bars, 100 μm. C Cell migration in the presence of FBS, EV-depleted FBS, or EV-depleted FBS supplemented with l-EV fraction from FBS (4 × 10 6 cells were treated with 6 × 10 8 EVs/ml in 1 ml). Dynamin inhibitor dynasore was applied at 40 μM. Cell migration areas are the wounded areas occupied by migrated cells after 12 h. Data show the means ± SD from 4 independent experiments. D Illustration of Rac1-containing EVs from HEK293 cell culture medium. E Cell migration in the presence of l-EV fraction from MIM I-BAR-expressing HEK293 cells (4 × 10 6 cells were treated with 1.4 × 10 9 EVs/ml in 1 ml). Dynasore was applied at 40 μM. Data show the means ± SD from 4 independent experiments. F Western blotting of Rac1 in the l-EV fractions of GFP or MIM I-BAR-expressing HEK293 cells and EV fractions from FBS. The number of EVs per lane was indicated. Representative blots from three technical replicates using the same lot of FBS are shown. G Western blotting of MIM in the EV fractions from FBS. A representative blot from the three technical replicates using the same lot of FBS is shown. H Cell migration under the l-EV fraction from FBS treated with the Rac1 inhibitor EHT1864 at 20 μM. 4 × 10 6 cells were treated with 6 × 10 8 EVs/ml in 1 ml. Data show the means ± SD from 3 independent experiments. Statistical significance was performed by one-way ANOVA with Tukey’s honestly significant difference (HSD) test. Source data are provided as a file.

    Article Snippet: To inhibit Rac1 in EVs, EHT1864 (TargetMol, #T6483) was added to the l-EV fraction from FBS at a final concentration of 20 μM, and the solution was incubated for 45 min at 37 °C.

    Techniques: Migration, Cell Culture, Wound Healing Assay, Expressing, Western Blot

    Analysis of cross-sensitivity of parental A2780 and Doxo-resistant A2780ADR cells to selected inhibitors of DDR- and DNA repair-related mechanisms. Logarithmically growing parental A2780 and A2780ADR variant cells were treated with selected pharmacological inhibitors of DNA repair (olaparib and niraparib), DDR (prexasertib and rabusertib), HDAC (ricolinistat and entinostat), Rac1 GTPase (EHT1864 and Ehop16), drug transport (verapamil) and Topo II (dexrazoxane) at the indicated concentrations. At 72 h after drug addition, viability was monitored by use of the AlamarBlue assay as described in methods. Data shown are the mean ± SD from three independent experiments each performed in biological quadruplicates (n=3; n=4). Dashed lines indicate inhibitory concentrations (IC 20 and IC 50 ). Data obtained from treatment period of 24 h are presented in . For IC 50 after 24 h and 72 h see . Doxo, doxorubicin; DDR, DNA damage response; HDAC, histone deacetylase; SD, standard deviation; EHT, Rac1 inhibitor EHT1864.

    Journal: International Journal of Oncology

    Article Title: Overcoming acquired doxorubicin resistance of ovarian carcinoma cells by verapamil-mediated promotion of DNA damage-driven cytotoxicity

    doi: 10.3892/ijo.2026.5861

    Figure Lengend Snippet: Analysis of cross-sensitivity of parental A2780 and Doxo-resistant A2780ADR cells to selected inhibitors of DDR- and DNA repair-related mechanisms. Logarithmically growing parental A2780 and A2780ADR variant cells were treated with selected pharmacological inhibitors of DNA repair (olaparib and niraparib), DDR (prexasertib and rabusertib), HDAC (ricolinistat and entinostat), Rac1 GTPase (EHT1864 and Ehop16), drug transport (verapamil) and Topo II (dexrazoxane) at the indicated concentrations. At 72 h after drug addition, viability was monitored by use of the AlamarBlue assay as described in methods. Data shown are the mean ± SD from three independent experiments each performed in biological quadruplicates (n=3; n=4). Dashed lines indicate inhibitory concentrations (IC 20 and IC 50 ). Data obtained from treatment period of 24 h are presented in . For IC 50 after 24 h and 72 h see . Doxo, doxorubicin; DDR, DNA damage response; HDAC, histone deacetylase; SD, standard deviation; EHT, Rac1 inhibitor EHT1864.

    Article Snippet: Chemicals were obtained from the following providers: Entinostat (MS-275) was obtained from Selleck Chemicals, Doxo from STADA Consumer Health & STADAPHARM GmbH, etoposide, Ehop16, prexasertib (AZD-7762) and dexrazoxane were from MilliporeSigma, cisplatin from Accord Healthcare GmbH, olaparib from APeXBIO Technology LLC, niraparib from MedChemExpress, EHT1864 was purchased from Tocris Bioscience, rabusertib (LY2603618) and ricolinostat (ACY-1215) from MedChemExpress and verapamil (Ver) from Thermo Fisher Scientific, Inc.

    Techniques: Variant Assay, Drug Transport Assay, Alamar Blue Assay, Histone Deacetylase Assay, Standard Deviation

    Combined treatment of A2780ADR with Doxo and selected inhibitors causes synergistic toxicity. (A) Logarithmically growing Doxo resistant A2780ADR cells were co-treated with Doxo and selected pharmacological inhibitors at the indicated concentrations. At 72 h after drug addition, viability was monitored by use of the AlamarBlue assay and CI was calculated as described in methods. Data shown are the mean ± SD from three independent experiments each performed in biological quadruplicates (n=3; n=4). (B) Intracellular Doxo fluorescence was measured by flow cytometry-based method after co-treatment with Doxo and selected pharmacological inhibitors as described in methods. To measure drug export, Doxo pulse-treated cells were post-incubated for 6 h in the absence of the drug before fluorescence was monitored. Data shown in the left panel are representative results obtained from flow cytometry analyses. C, control; I, import, E, export. The histogram in the right panel depicts quantitative data obtained from n=3 independent experiments each performed in biological triplicates (n=3). Statistical significance: * P≤0.05; ** P≤0.001. Doxo, doxorubicin; CI, combination index; SD, standard deviation; EST, entinostat; EHT, Rac1 inhibitor EHT1864; Dex, dexrazoxane; Rab, rabusertib; Ver, verapamil.

    Journal: International Journal of Oncology

    Article Title: Overcoming acquired doxorubicin resistance of ovarian carcinoma cells by verapamil-mediated promotion of DNA damage-driven cytotoxicity

    doi: 10.3892/ijo.2026.5861

    Figure Lengend Snippet: Combined treatment of A2780ADR with Doxo and selected inhibitors causes synergistic toxicity. (A) Logarithmically growing Doxo resistant A2780ADR cells were co-treated with Doxo and selected pharmacological inhibitors at the indicated concentrations. At 72 h after drug addition, viability was monitored by use of the AlamarBlue assay and CI was calculated as described in methods. Data shown are the mean ± SD from three independent experiments each performed in biological quadruplicates (n=3; n=4). (B) Intracellular Doxo fluorescence was measured by flow cytometry-based method after co-treatment with Doxo and selected pharmacological inhibitors as described in methods. To measure drug export, Doxo pulse-treated cells were post-incubated for 6 h in the absence of the drug before fluorescence was monitored. Data shown in the left panel are representative results obtained from flow cytometry analyses. C, control; I, import, E, export. The histogram in the right panel depicts quantitative data obtained from n=3 independent experiments each performed in biological triplicates (n=3). Statistical significance: * P≤0.05; ** P≤0.001. Doxo, doxorubicin; CI, combination index; SD, standard deviation; EST, entinostat; EHT, Rac1 inhibitor EHT1864; Dex, dexrazoxane; Rab, rabusertib; Ver, verapamil.

    Article Snippet: Chemicals were obtained from the following providers: Entinostat (MS-275) was obtained from Selleck Chemicals, Doxo from STADA Consumer Health & STADAPHARM GmbH, etoposide, Ehop16, prexasertib (AZD-7762) and dexrazoxane were from MilliporeSigma, cisplatin from Accord Healthcare GmbH, olaparib from APeXBIO Technology LLC, niraparib from MedChemExpress, EHT1864 was purchased from Tocris Bioscience, rabusertib (LY2603618) and ricolinostat (ACY-1215) from MedChemExpress and verapamil (Ver) from Thermo Fisher Scientific, Inc.

    Techniques: Alamar Blue Assay, Fluorescence, Flow Cytometry, Incubation, Control, Standard Deviation

    Influence of combined treatment of A2780ADR with Doxo and selected inhibitors on DNA damage formation, proliferation and cell death. (A) At 24 h after treatment of logarithmically growing cells with the indicated concentrations of Doxo and inhibitors (EHT, 5 μ M; EST, 1 μ M; Ver, 50 μ M), the number of nuclear γH2AX-foci, 53BP1-foci, γH2AX/53BP1 co-localized foci and γH2AX pan-stained cells was analyzed as described in methods. The upper part of the figure shows representative images (total magnification, ×1,000). Quantitative data depicted in the histogram are the mean ± SD from n=5 microscopical images analyzed per experimental condition. * P≤0.05, ** P≤0.01, *** P≤0.001 mono-treatment vs. co-treatment; # P≤0.05, ## P≤0.01, ### P≤0.001 untreated vs. treated group). (B) Logarithmically growing Doxo resistant A2780ADR cells were co-treated with the indicated concentrations of Doxo and selected pharmacological inhibitors (EHT, 5 μ M; EST, 1 μ M; Ver, 50 μ M). At 24 h later, cells were pulse-labeled with EdU to monitor proliferation as described in methods and the percentage of EdU positive cells was determined microscopically (total magnification, ×400). Quantitative data shown in the histogram are the mean ± SD from five replicates. ** P≤0.05; ## P≤0.01; ### P≤0.001 (vs. untreated control). (C) PI staining of mono- and co-treated A2780ADR cells 72 h after treatment with Doxo (0.1 μ M) and pharmacological inhibitors (EHT, 5 μ M; EST, 1 μ M; Ver, 50 μ M). Left panel: representative images; right panel: percentage of PI positive cells (mean ± SD from n=5 microscopical images analyzed per experimental condition) (40× microscope objective). * P≤0.05; ** P≤0.01. mono-treatment vs. co-treatment; # P≤0.05; ## P≤0.01, Con vs treated group. Doxo, doxorubicin; EST, entinostat; EHT, Rac1 inhibitor EHT1864; Ver, verapamil; SD, standard deviation; PI, propidium iodide.

    Journal: International Journal of Oncology

    Article Title: Overcoming acquired doxorubicin resistance of ovarian carcinoma cells by verapamil-mediated promotion of DNA damage-driven cytotoxicity

    doi: 10.3892/ijo.2026.5861

    Figure Lengend Snippet: Influence of combined treatment of A2780ADR with Doxo and selected inhibitors on DNA damage formation, proliferation and cell death. (A) At 24 h after treatment of logarithmically growing cells with the indicated concentrations of Doxo and inhibitors (EHT, 5 μ M; EST, 1 μ M; Ver, 50 μ M), the number of nuclear γH2AX-foci, 53BP1-foci, γH2AX/53BP1 co-localized foci and γH2AX pan-stained cells was analyzed as described in methods. The upper part of the figure shows representative images (total magnification, ×1,000). Quantitative data depicted in the histogram are the mean ± SD from n=5 microscopical images analyzed per experimental condition. * P≤0.05, ** P≤0.01, *** P≤0.001 mono-treatment vs. co-treatment; # P≤0.05, ## P≤0.01, ### P≤0.001 untreated vs. treated group). (B) Logarithmically growing Doxo resistant A2780ADR cells were co-treated with the indicated concentrations of Doxo and selected pharmacological inhibitors (EHT, 5 μ M; EST, 1 μ M; Ver, 50 μ M). At 24 h later, cells were pulse-labeled with EdU to monitor proliferation as described in methods and the percentage of EdU positive cells was determined microscopically (total magnification, ×400). Quantitative data shown in the histogram are the mean ± SD from five replicates. ** P≤0.05; ## P≤0.01; ### P≤0.001 (vs. untreated control). (C) PI staining of mono- and co-treated A2780ADR cells 72 h after treatment with Doxo (0.1 μ M) and pharmacological inhibitors (EHT, 5 μ M; EST, 1 μ M; Ver, 50 μ M). Left panel: representative images; right panel: percentage of PI positive cells (mean ± SD from n=5 microscopical images analyzed per experimental condition) (40× microscope objective). * P≤0.05; ** P≤0.01. mono-treatment vs. co-treatment; # P≤0.05; ## P≤0.01, Con vs treated group. Doxo, doxorubicin; EST, entinostat; EHT, Rac1 inhibitor EHT1864; Ver, verapamil; SD, standard deviation; PI, propidium iodide.

    Article Snippet: Chemicals were obtained from the following providers: Entinostat (MS-275) was obtained from Selleck Chemicals, Doxo from STADA Consumer Health & STADAPHARM GmbH, etoposide, Ehop16, prexasertib (AZD-7762) and dexrazoxane were from MilliporeSigma, cisplatin from Accord Healthcare GmbH, olaparib from APeXBIO Technology LLC, niraparib from MedChemExpress, EHT1864 was purchased from Tocris Bioscience, rabusertib (LY2603618) and ricolinostat (ACY-1215) from MedChemExpress and verapamil (Ver) from Thermo Fisher Scientific, Inc.

    Techniques: Staining, Labeling, Control, Microscopy, Standard Deviation

    Effects of co-treatment of Doxo with selected pharmacological inhibitors on non-malignant cells. Logarithmically growing (A) non-malignant murine HL-1 cardiomyocyte cells, (B) mESC and (C) hiPSC were treated with the indicated concentrations of Doxo and selected pharmacological inhibitors for 72 h. Afterwards, cell viability was analyzed by the use of the AlamarBlue assay as described in methods. Data shown are the mean ± SD from n=1-3 independent experiments each performed in biological quadruplicates. * P≤0.05; ** P≤0.001 (mono- vs. co-treated group). Dashed lines indicate 50% viability. Doxo, doxorubicin; mESC, murine embryonic stem cells; hiPSC, human induced pluripotent stem cells; EHT, Rac1 inhibitor EHT1864; EST, entinostat; Ver, verapamil.

    Journal: International Journal of Oncology

    Article Title: Overcoming acquired doxorubicin resistance of ovarian carcinoma cells by verapamil-mediated promotion of DNA damage-driven cytotoxicity

    doi: 10.3892/ijo.2026.5861

    Figure Lengend Snippet: Effects of co-treatment of Doxo with selected pharmacological inhibitors on non-malignant cells. Logarithmically growing (A) non-malignant murine HL-1 cardiomyocyte cells, (B) mESC and (C) hiPSC were treated with the indicated concentrations of Doxo and selected pharmacological inhibitors for 72 h. Afterwards, cell viability was analyzed by the use of the AlamarBlue assay as described in methods. Data shown are the mean ± SD from n=1-3 independent experiments each performed in biological quadruplicates. * P≤0.05; ** P≤0.001 (mono- vs. co-treated group). Dashed lines indicate 50% viability. Doxo, doxorubicin; mESC, murine embryonic stem cells; hiPSC, human induced pluripotent stem cells; EHT, Rac1 inhibitor EHT1864; EST, entinostat; Ver, verapamil.

    Article Snippet: Chemicals were obtained from the following providers: Entinostat (MS-275) was obtained from Selleck Chemicals, Doxo from STADA Consumer Health & STADAPHARM GmbH, etoposide, Ehop16, prexasertib (AZD-7762) and dexrazoxane were from MilliporeSigma, cisplatin from Accord Healthcare GmbH, olaparib from APeXBIO Technology LLC, niraparib from MedChemExpress, EHT1864 was purchased from Tocris Bioscience, rabusertib (LY2603618) and ricolinostat (ACY-1215) from MedChemExpress and verapamil (Ver) from Thermo Fisher Scientific, Inc.

    Techniques: Alamar Blue Assay

    Hypothetical model of Ver-mediated resensitization of Doxo-resistant tumor cells. It was hypothesized that Ver increased the anticancer efficacy of Doxo in a synergistic manner in anticancer drug resistant ovarian A2780ADR cells. This is probably due to inhibition of MDR1-mediated drug export, leading to higher intracellular steady-state concentrations of Doxo. In consequence, Doxo-mediated Topo II poisoning is promoted, eventually causing increased DNA damage (that is, DSB) formation and activation of DSB-related pro-toxic signaling mechanism which impair cell proliferation and stimulate cell death- and senescence-related pathways. Apart from verapamil, inhibition of Rac1 GTPase-regulated signaling by EHT1864 and inhibition of HDAC class I by entinostat are also useful to overcome acquired Doxo resistance of A2780ADR cells, yet with the exact molecular mechanisms involved being unclear. Ver, verapamil; Doxo, doxorubicin; DSB, DNA double-strand breaks.

    Journal: International Journal of Oncology

    Article Title: Overcoming acquired doxorubicin resistance of ovarian carcinoma cells by verapamil-mediated promotion of DNA damage-driven cytotoxicity

    doi: 10.3892/ijo.2026.5861

    Figure Lengend Snippet: Hypothetical model of Ver-mediated resensitization of Doxo-resistant tumor cells. It was hypothesized that Ver increased the anticancer efficacy of Doxo in a synergistic manner in anticancer drug resistant ovarian A2780ADR cells. This is probably due to inhibition of MDR1-mediated drug export, leading to higher intracellular steady-state concentrations of Doxo. In consequence, Doxo-mediated Topo II poisoning is promoted, eventually causing increased DNA damage (that is, DSB) formation and activation of DSB-related pro-toxic signaling mechanism which impair cell proliferation and stimulate cell death- and senescence-related pathways. Apart from verapamil, inhibition of Rac1 GTPase-regulated signaling by EHT1864 and inhibition of HDAC class I by entinostat are also useful to overcome acquired Doxo resistance of A2780ADR cells, yet with the exact molecular mechanisms involved being unclear. Ver, verapamil; Doxo, doxorubicin; DSB, DNA double-strand breaks.

    Article Snippet: Chemicals were obtained from the following providers: Entinostat (MS-275) was obtained from Selleck Chemicals, Doxo from STADA Consumer Health & STADAPHARM GmbH, etoposide, Ehop16, prexasertib (AZD-7762) and dexrazoxane were from MilliporeSigma, cisplatin from Accord Healthcare GmbH, olaparib from APeXBIO Technology LLC, niraparib from MedChemExpress, EHT1864 was purchased from Tocris Bioscience, rabusertib (LY2603618) and ricolinostat (ACY-1215) from MedChemExpress and verapamil (Ver) from Thermo Fisher Scientific, Inc.

    Techniques: Inhibition, Activation Assay